Cargando…

Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression

BACKGROUND: There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer’s disease (AD). In this work, a temporal lobe composite (Eτ) volume of interest (VOI) was evaluated in a longitudinal flortaucipir cohort and compared to a previously described global neocortical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotari, Vikas, Southekal, Sudeepti, Navitsky, Michael, Kennedy, Ian A., Lu, Ming, Morris, Amanda, Zimmer, Jennifer Ann, Fleisher, Adam S., Mintun, Mark A., Devous, Michael D., Pontecorvo, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972744/ https://www.ncbi.nlm.nih.gov/pubmed/36855201 http://dx.doi.org/10.1186/s13195-023-01160-6

Ejemplares similares

A multicentre longitudinal study of flortaucipir ((18)F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
por: Pontecorvo, Michael J, et al.
Publicado: (2019)

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
por: Pontecorvo, Michael J., et al.
Publicado: (2017)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
por: Pontecorvo, Michael J., et al.
Publicado: (2020)

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
por: Shcherbinin, Sergey, et al.
Publicado: (2023)

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials
por: Lu, Ming, et al.
Publicado: (2021)

Topographic staging of tau positron emission tomography images
por: Schwarz, Adam J., et al.
Publicado: (2018)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
por: Makaretz, Sara J, et al.
Publicado: (2018)

SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline
por: Toledo, Jon B., et al.
Publicado: (2022)

Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE
por: Alosco, Michael L., et al.
Publicado: (2021)

Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [(18)F]flortaucipir study
por: O’Connor, Antoinette, et al.
Publicado: (2023)

Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET
por: Hong, Jimin, et al.
Publicado: (2022)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Cryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir
por: Shi, Yang, et al.
Publicado: (2023)

International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
por: Tian, Mei, et al.
Publicado: (2022)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation
por: Wright, Justin P., et al.
Publicado: (2022)

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
por: Alosco, Michael L., et al.
Publicado: (2022)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [(18)F]Flortaucipir PET
por: Risacher, Shannon L., et al.
Publicado: (2018)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
por: Costoya-Sánchez, Alejandro, et al.
Publicado: (2023)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
por: Pontecorvo, Michael J, et al.
Publicado: (2011)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [(18)F]-APN-1607 Study
por: Zhang, Huiwei, et al.
Publicado: (2021)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
por: Whitwell, Jennifer L., et al.
Publicado: (2019)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation
por: Schwarz, Christopher G., et al.
Publicado: (2021)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v9gubiuch0ggep9p4f6dvtgdns